Funding

Seawolf Therapeutics Raises $100M Across Seed and Series A Funding

Nov 17, 2026 | By Devin Jacobs

Seawolf Therapeutics Raises $100M Across Seed and Series A Funding

SUMMARY

  • Seawolf Therapeutics raised $100 million in funding.
  • The funds will support its drug research.
  • Seawolf develops treatments for metabolic and rare diseases.

Seawolf Therapeutics, a San Diego-based biotechnology company developing DNA delivery technology, has raised $100 million across Seed and Series A funding rounds. Versant Ventures led the Seed round, while the Series A was co-led by Versant Ventures, MPM BioImpact and Novartis Venture Fund (NVF).

Other investors included Eli Lilly and Company, CRISPR Therapeutics AG, Sixty Degree Capital, Alexandria Venture Investments, Pathway to Cures and others.

The company will use the funding to advance its drug development programmes, including its lead metabolic disease programme and a research collaboration with Sanofi.

What is Seawolf Therapeutics?

Founded by Elizabeth Alcamo, Seawolf Therapeutics is a biotechnology company developing treatments using its proprietary TRIDENT DNA delivery platform.

Read More:Focus Financial Partners Receives Investment From Apollo Funds

TRIDENT, which stands for Targeted RNA Induced DNA Expression via Nuclear Translocation, uses lipid nanoparticles (LNPs) to deliver DNA into cells. The technology is designed to help cells produce therapeutic proteins over longer periods.

Unlike RNA-based treatments, which often provide short term protein expression, Seawolfs platform aims to deliver longer lasting results. It is also designed to allow repeat dosing, giving researchers the ability to adjust or supplement treatment over time.

Seawolf is developing the technology for several medical applications, including replacing faulty genes and producing therapeutic proteins to treat metabolic and rare diseases.

About Seawolf Therapeutics

How Much Funding Has Seawolf Therapeutics Raised?

Seawolf Therapeutics has raised $100 million across its Seed and Series A rounds.

The Seed round was led by Versant Ventures. The Series A financing was co-led by Versant Ventures, MPM BioImpact and Novartis Venture Fund.

The company has not disclosed a breakdown of the funding amounts between the two rounds.

Who Invested in Seawolf Therapeutics Seed and Series A Rounds?

The Seed round was led by Versant Ventures.

The Series A round was co-led by:

  • Versant Ventures
  • MPM BioImpact
  • Novartis Venture Fund (NVF)

Other participating investors included:

  • Eli Lilly and Company
  • CRISPR Therapeutics AG
  • Sixty Degree Capital
  • Alexandria Venture Investments
  • Pathway to Cures
  • Other investors

Why the Funding Matters

Seawolf plans to use the capital to advance its portfolio of treatments based on the TRIDENT platform. A key priority is developing it's lead programme for metabolic diseases.

The company will also use the funding to carry out its multi-target research collaboration with Sanofi.

Under a separate agreement, Seawolf and Sanofi will work on treatments for bleeding disorders and other undisclosed medical conditions. The agreement includes the potential for up to $1.2 billion in research, development and commercial milestone payments, along with tiered royalties on product sales.

Seawolf Therapeutics funding

Who founded Seawolf Therapeutics?

Seawolf Therapeutics was founded by Elizabeth Alcamo. The company is headquartered in San Diego, California.

“Seawolf is charting a new course in patient care through LNP-based DNA medicines,” said Elizabeth Alcamo, Ph.D., president and CEO. “With a strong syndicate of investors and our collaboration with Sanofi, we are well-positioned to execute on our next stage of growth, which will include advancing our lead program for metabolic diseases and collaborating with Sanofi in its mission to develop therapies for patient unmet needs.”

Market and Business Growth

Seawolf has demonstrated the potential of its TRIDENT technology in preclinical studies involving primate, and mice. These studies covered metabolic and rare disease applications.

The company say's the platform is designed to combine long lasting therapeutic protein production with the ability to administer repeat doses. It is also being developed for use across multiple treatment areas.

Its collaboration with Sanofi add's another development programme focused on bleeding disorders and other indications.

What Happens Next?

Seawolf will focus on advancing its metabolic disease programme and developing additional treatments using the TRIDENT platform.

The company will also move forward with its research collaboration with Sanofi, targeting bleeding disorders and other undisclosed conditions. Its broader goal is to develop DNA based therapies that provide longer lasting effects and can be administered repeatedly.

Read More:TipHaus Receives Investment From Vista Equity Partners

Recommended Stories for You